PMEL and melanoma: Here, we used a tissue microarray (TMA) cohort which includes 60 Itx treated melanoma patients to identify potential predictive markers of survival and response using a 44plex panel of immune markers collected sequentially and quantified in three different compartments: in macrophage, leukocyte and the melanocyte ROI, defined by CD68+, CD45+ and S100+HMB45+ respectively.